GT Biopharma, Inc. (NASDAQ:GTBP) Sees Large Increase in Short Interest

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 2,111,313 shares, an increase of 45.3% from the December 15th total of 1,453,242 shares. Based on an average daily volume of 2,660,073 shares, the days-to-cover ratio is presently 0.8 days. Currently, 20.6% of the company’s stock are short sold. Currently, 20.6% of the company’s stock are short sold. Based on an average daily volume of 2,660,073 shares, the days-to-cover ratio is presently 0.8 days.

GT Biopharma Price Performance

GTBP opened at $0.75 on Friday. GT Biopharma has a fifty-two week low of $0.54 and a fifty-two week high of $3.85. The firm has a market capitalization of $7.94 million, a P/E ratio of -0.22 and a beta of 1.17. The company’s 50-day moving average is $0.73 and its 200 day moving average is $1.08.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.45). On average, equities research analysts expect that GT Biopharma will post -6.79 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in GT Biopharma stock. SeaCrest Wealth Management LLC bought a new position in shares of GT Biopharma, Inc. (NASDAQ:GTBP) during the fourth quarter, according to its most recent filing with the SEC. The fund bought 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned 0.47% of GT Biopharma at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.15% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on GTBP. Weiss Ratings reaffirmed a “sell (e)” rating on shares of GT Biopharma in a research note on Monday, December 29th. Wall Street Zen cut shares of GT Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, September 20th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

About GT Biopharma

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).